Smart-Money SignalNeutral · 50/100— Insiders are net buyers over 90 days ($27K, 5 buys vs 0 sales)
Revenue$218.3M
Net Income$78.4M
EPS$-2.59
Market Cap$2.4B
Price Performance
Historical data including institutional events
Company Profile
J
Jon P. Stonehouse
CEO & Executive Director
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
